• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's Pre-Market Session

    5/1/24 8:06:50 AM ET
    $AKAN
    $BRNS
    $CVRX
    $CVS
    Medicinal Chemicals and Botanical Products
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AKAN alert in real time by email

    Gainers

    • Akanda (NASDAQ:AKAN) shares moved upwards by 69.1% to $0.16 during Wednesday's pre-market session. The company's market cap stands at $1.8 million.
    • NanoVibronix (NASDAQ:NAOV) shares moved upwards by 25.17% to $0.92. The market value of their outstanding shares is at $2.5 million.
    • Predictive Oncology (NASDAQ:POAI) shares increased by 23.4% to $1.74. The market value of their outstanding shares is at $7.0 million.
    • Lucy Scientific Discovery (NASDAQ:LSDI) shares moved upwards by 19.0% to $0.99. The company's market cap stands at $1.7 million.
    • Emergent BioSolutions (NYSE:EBS) stock moved upwards by 18.08% to $2.22. The company's market cap stands at $116.3 million. As per the press release, Q1 earnings came out today.
    • IGC Pharma (AMEX:IGC) stock moved upwards by 17.15% to $0.64. The market value of their outstanding shares is at $42.4 million.

    Losers

    • CVRx (NASDAQ:CVRX) stock fell 20.5% to $12.33 during Wednesday's pre-market session. The company's market cap stands at $266.2 million. As per the press release, Q1 earnings came out yesterday.
    • NRX Pharmaceuticals (NASDAQ:NRXP) shares declined by 18.22% to $2.11. The company's market cap stands at $22.1 million.
    • BiomX (AMEX:PHGE) shares decreased by 14.41% to $0.41. The market value of their outstanding shares is at $22.6 million.
    • Cyclacel Pharmaceuticals (NASDAQ:CYCC) stock decreased by 11.8% to $1.87. The company's market cap stands at $2.4 million.
    • CVS Health (NYSE:CVS) stock decreased by 11.67% to $59.81. The market value of their outstanding shares is at $75.3 billion. As per the news, the Q1 earnings report came out today.
    • Barinthus Biotherapeutics (NASDAQ:BRNS) stock decreased by 8.79% to $1.87. The market value of their outstanding shares is at $72.7 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AKAN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AKAN
    $BRNS
    $CVRX
    $CVS

    CompanyDatePrice TargetRatingAnalyst
    CVS Health Corporation
    $CVS
    3/12/2026$94.00Mkt Perform → Outperform
    Bernstein
    CVS Health Corporation
    $CVS
    10/14/2025$91.00Buy
    Goldman
    NRX Pharmaceuticals Inc.
    $NRXP
    9/8/2025$40.00Buy
    H.C. Wainwright
    CVS Health Corporation
    $CVS
    8/18/2025$79.00Neutral → Buy
    UBS
    CVS Health Corporation
    $CVS
    8/14/2025$82.00Neutral → Outperform
    Robert W. Baird
    CVRx Inc.
    $CVRX
    5/9/2025$7.00Neutral → Underweight
    Analyst
    NRX Pharmaceuticals Inc.
    $NRXP
    4/2/2025$18.00Buy
    BTIG Research
    CVS Health Corporation
    $CVS
    2/13/2025$55.00 → $75.00Market Perform → Outperform
    Leerink Partners
    More analyst ratings

    $AKAN
    $BRNS
    $CVRX
    $CVS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Jain Mudit K. bought $297,592 worth of shares (46,800 units at $6.36) (SEC Form 4)

    4 - CVRx, Inc. (0001235912) (Issuer)

    2/23/26 6:00:12 AM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    Director Jain Mudit K. bought $2,785 worth of shares (600 units at $4.64), increasing direct ownership by 12% to 5,650 units (SEC Form 4)

    4 - CVRx, Inc. (0001235912) (Issuer)

    2/18/26 5:22:25 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    EVP and President, Aetna Nelson Steven H bought $1,289 worth of shares (24 units at $53.70) (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    1/27/26 5:20:15 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $AKAN
    $BRNS
    $CVRX
    $CVS
    SEC Filings

    View All

    BiomX Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - BiomX Inc. (0001739174) (Filer)

    3/19/26 9:25:39 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-KT filed by IGC Pharma Inc.

    10-KT - IGC Pharma, Inc. (0001326205) (Filer)

    3/18/26 4:02:27 PM ET
    $IGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Barinthus Biotherapeutics plc

    10-K - Barinthus Biotherapeutics plc. (0001828185) (Filer)

    3/13/26 8:13:15 AM ET
    $BRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKAN
    $BRNS
    $CVRX
    $CVS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    CVS Health upgraded by Bernstein with a new price target

    Bernstein upgraded CVS Health from Mkt Perform to Outperform and set a new price target of $94.00

    3/12/26 8:38:26 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Goldman initiated coverage on CVS Health with a new price target

    Goldman initiated coverage of CVS Health with a rating of Buy and set a new price target of $91.00

    10/14/25 8:48:20 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    H.C. Wainwright initiated coverage on NRx Pharmaceuticals with a new price target

    H.C. Wainwright initiated coverage of NRx Pharmaceuticals with a rating of Buy and set a new price target of $40.00

    9/8/25 8:58:39 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKAN
    $BRNS
    $CVRX
    $CVS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $AKAN
    $BRNS
    $CVRX
    $CVS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    BiomX CEO Issues Letter to Stockholders

    CEO Letter to Stockholders highlights the Company's strategic and financial reset designed to strengthen BiomX in the near term and unlock future growth opportunitiesDOVER, Del., March 19, 2026 /PRNewswire/ -- BiomX Inc. (NYSE:PHGE), today released the following letter from its Chief Executive Officer to stockholders. Dear Stockholders,Over the past several weeks, BiomX has taken decisive steps to reshape its leadership, priorities, and financial structure. Leadership has evolved, strategic priorities have been sharpened, and we are taking concrete steps intended to improve the Company's financial and operational structure. These changes have not been easy, but they are necessary to put Biom

    3/19/26 9:15:00 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) to Report Full Year 2025 Financial Results and Provide a Corporate Update on March 24, 2026

    WILMINGTON, Del., March 19, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will host a conference call at 8:00am ET on Tuesday, March 24, 2026. In addition to reviewing the Company's financial results for the fiscal year ended December 31, 2025, the Company will provide an update on the significant progress achieved across its drug development programs and the HOPE Therapeutics clinical network, milestones that bring the Company closer to its founding mission of preventing suicide and transforming the treatment of depression and PTSD to improve the lives of patient

    3/19/26 7:00:00 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CVS Health declares quarterly dividend

    WOONSOCKET, R.I., March 18, 2026 /PRNewswire/ -- CVS Health® (NYSE: CVS) has announced that its board of directors has approved a quarterly dividend of sixty-six and one-half cents ($0.665 cents) per share on the Common Stock of the Corporation. The dividend is payable on May 4, 2026, to holders of record on April 23, 2026. About CVS HealthCVS Health is a leading health solutions company building a world of health around every consumer, wherever they are. As of December 31, 2025, the Company had approximately 9,000 retail pharmacy locations, more than 1,000 walk-in and primary c

    3/18/26 5:15:00 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    SEC Form 4 filed by Yeganeh Reuven

    4 - BiomX Inc. (0001739174) (Issuer)

    3/18/26 5:47:41 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Medical Officer Adamson Philip B. was granted 41,000 shares and sold $9,973 worth of shares (1,262 units at $7.90), increasing direct ownership by 182% to 61,578 units (SEC Form 4)

    4 - CVRx, Inc. (0001235912) (Issuer)

    3/16/26 4:16:14 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    Director Yeganeh Reuven sold $3,350,000 worth of shares (670,000 units at $5.00) and converted options into 670,000 shares (SEC Form 4)

    4 - BiomX Inc. (0001739174) (Issuer)

    3/13/26 4:30:02 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AKAN
    $BRNS
    $CVRX
    $CVS
    Leadership Updates

    Live Leadership Updates

    View All

    BiomX Names Michael Oster as Chief Executive Officer, David Rokach Chief Financial Officer to Support Next Phase of Growth

    Seasoned financial leaders join BiomX to support strategic execution and advancement of the companyDOVER, Del. and NESS ZIONA, Israel, March 9, 2026 /PRNewswire/ -- BiomX Inc. (NYSE:PHGE), a clinical-stage company developing natural and engineered phage therapies designed to target and destroy harmful bacteria in chronic diseases, today announced the appointment of Michael Oster as Chief Executive Officer and David Rokach as Chief Financial Officer. Oster brings extensive experience in corporate strategy, mergers and acquisitions, and operational leadership across capital-intensive industries including energy, infrastructure, and industrial sectors. Throughout his career, he has led complex

    3/9/26 9:00:00 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Emergent BioSolutions Announces Appointment of John D. Fowler, Jr. to Board of Directors

    GAITHERSBURG, Md., March 03, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the appointment of John D. Fowler, Jr. to its board of directors effective March 1, 2026. Mr. Fowler brings more than three decades of leadership experience across the healthcare and financial services sectors. He will serve on the Audit and Finance Committee. "We're pleased to welcome John to the board of directors at this important point in the company's ongoing turnaround and transformation," said Dr. Zsolt Harsanyi, Ph.D., chairman of the board. "John's deep experience in healthcare and financial markets will provide valuable insight as the company continues to execute against i

    3/3/26 8:00:00 AM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NRx Pharmaceuticals (Nasdaq: NRXP) Appoints Prof. Joshua Brown MD, PhD, as Chief Medical Innovation Officer

    Prof. Brown is a pioneer in Transcranial Magnetic Stimulation (TMS) and serves as current President of the Clinical TMS Society and Editor-in-Chief of the Transcranial Magnetic Stimulation journal.Extensive publication history in the science of neuroplasticity and its relationship to healing depression and PTSD.Unique background in charting a path for forward deployment of TMS with neuroplastic medication to treat depression and PTSD in military personnel, veterans, and first responders. WILMINGTON, Del., March 02, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), a clinical-stage biopharmaceutical company, today announced that it has appointed Prof. Joshua C. Brown, MD, P

    3/2/26 7:00:00 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKAN
    $BRNS
    $CVRX
    $CVS
    Financials

    Live finance-specific insights

    View All

    NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) to Report Full Year 2025 Financial Results and Provide a Corporate Update on March 24, 2026

    WILMINGTON, Del., March 19, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will host a conference call at 8:00am ET on Tuesday, March 24, 2026. In addition to reviewing the Company's financial results for the fiscal year ended December 31, 2025, the Company will provide an update on the significant progress achieved across its drug development programs and the HOPE Therapeutics clinical network, milestones that bring the Company closer to its founding mission of preventing suicide and transforming the treatment of depression and PTSD to improve the lives of patient

    3/19/26 7:00:00 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CVS Health declares quarterly dividend

    WOONSOCKET, R.I., March 18, 2026 /PRNewswire/ -- CVS Health® (NYSE: CVS) has announced that its board of directors has approved a quarterly dividend of sixty-six and one-half cents ($0.665 cents) per share on the Common Stock of the Corporation. The dividend is payable on May 4, 2026, to holders of record on April 23, 2026. About CVS HealthCVS Health is a leading health solutions company building a world of health around every consumer, wherever they are. As of December 31, 2025, the Company had approximately 9,000 retail pharmacy locations, more than 1,000 walk-in and primary c

    3/18/26 5:15:00 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    CVS Health Foundation Invests $2.24 Million to Strengthen Community Health in Charlotte's Historic West End

    Health Zones effort aims to improve health care access, healthy food and chronic condition support in CharlotteCHARLOTTE, N.C., March 18, 2026 /PRNewswire/ -- The CVS Health Foundation today announced the launch of its Health Zone in Charlotte with a $2.24 million investment in the Westside Wellness Collab, led by Local Initiatives Support Corporation (LISC) Charlotte to expand access to health care, healthy food and chronic condition support in Charlotte's Historic West End. "Families deserve access to quality care, healthy food and the support networks that make long‑term well

    3/18/26 9:00:00 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $AKAN
    $BRNS
    $CVRX
    $CVS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Cyclacel Pharmaceuticals Inc.

    SC 13G/A - Cyclacel Pharmaceuticals, Inc. (0001130166) (Subject)

    11/14/24 7:21:58 PM ET
    $CYCC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by NanoVibronix Inc.

    SC 13G/A - NanoVibronix, Inc. (0001326706) (Subject)

    11/14/24 5:17:34 PM ET
    $NAOV
    Industrial Specialties
    Health Care

    SEC Form SC 13G filed by Cyclacel Pharmaceuticals Inc.

    SC 13G - Cyclacel Pharmaceuticals, Inc. (0001130166) (Subject)

    11/14/24 3:27:04 PM ET
    $CYCC
    Biotechnology: Pharmaceutical Preparations
    Health Care